111Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Dofetilide is a new class III antiarrhythmic drug that produces both its antiarrhythmic and toxic effects through blockade of I(Kr). Dofetilide has been shown to be effective for conversion of persistent atrial fibrillation and for maintenance of sinus rhythm after pharmacological and electrical cardioversion. Dofetilide has a narrow therapeutic range. Dosage should be adjusted on the basis of renal function and its pharmacological effect on the QT interval. A role for dofetilide has not yet been demonstrated for primary prevention of sudden death in patients with heart failure or after myocardial infarction or among those with a history of sustained ventricular tachycardia or fibrillation. Appropriate use of dofetilide by clinicians will require careful attention to renal function and the potential for drug interactions. In-hospital monitoring during therapy initiation is recommended to reduce the possibility of potentially fatal proarrhythmia.

Cite

CITATION STYLE

APA

Mounsey, J. P., & DiMarco, J. P. (2000, November 21). Dofetilide. Circulation. Lippincott Williams and Wilkins. https://doi.org/10.1161/01.CIR.102.21.2665

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free